Drugs / RPM CD19-mbIL15-CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04844086 | Mar 2021 → May 2022 | B-cell acute lymphoblastic leukemia, follicular lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +1 | Eden BioCell Ltd. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPM CD19-mbIL15-CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04844086 ↗ |
| Modality | Cell therapy | “anti-CD19 autologous chimeric antigen receptor T-cells infusion produced by rapid personalized manufacture” NCT04844086 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT04844086 ↗ |
| Target | CD19 | “anti-CD19 autologous chimeric antigen receptor T-cells” NCT04844086 ↗ |